A cell-free workflow for detecting and characterizing RiPP recognition element-precursor peptide interactions DOI Creative Commons
Derek A. Wong, Zachary M. Shaver, Maria D. Cabezas

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Март 26, 2024

Abstract Post-translational modifications (PTMs) are important for the stability and function of many therapeutic proteins peptides. Current methods studying engineering PTM installing often suffer from low-throughput experimental techniques. Here we describe a generalizable, in vitro workflow coupling cell-free protein synthesis (CFPS) with AlphaLISA rapid expression testing proteins. We apply our to two representative classes peptide therapeutics: ribosomally synthesized post-translationally modified peptides (RiPPs) conjugate vaccines. First, demonstrate how can be used characterize binding activity RiPP recognition elements, an first step biosynthesis, integrated into biodiscovery pipeline computationally predicted products. Then, adapt study engineer oligosaccharyltransferases (OSTs) involved vaccine production, enabling identification mutant OSTs sites within carrier that enable high efficiency production In total, expect will accelerate design-build-test cycles PTMs.

Язык: Английский

Streptococcus pneumoniae serotype distribution in low- and middle-income countries of South Asia: Do we need to revisit the pneumococcal vaccine strategy? DOI Creative Commons

Priya Dhawale,

Sanket Shah, Kaushal Sharma

и другие.

Human Vaccines & Immunotherapeutics, Год журнала: 2025, Номер 21(1)

Опубликована: Фев. 25, 2025

S. pneumoniae serotypes responsible for pneumococcal disease differ with respect to severity, invasiveness, antimicrobial susceptibility, geographies, immunization history, age groups, and time. Although PCVs have blunted the burden, they are plagued numerous challenges, especially emergence of NVTs. In this review, we show that there diverse serotypes, NVTs, causing diseases in LMICs South Asia across different studies conducted between 2012 2024. We propose pharmaceutical/biotech companies should tailor/customize as per region-specific serotype prevalence based on surveillance data. Furthermore, protein-based vaccines, or WCVs, been explored can serve viable alternatives address limitations associated PCVs. However, robust warranted geographies demonstrate its efficacy safety clinical trials well real-world effectiveness these promising candidates.

Язык: Английский

Процитировано

1
Pneumococcal vaccines in China DOI Creative Commons
Shanshan Wang, Li Guo, Qiong Chen

и другие.

Human Vaccines & Immunotherapeutics, Год журнала: 2025, Номер 21(1)

Опубликована: Янв. 30, 2025

Invasive pneumococcal disease (IPD) is a serious global public health problem and the leading cause of morbidity mortality in children adults China. Thus, developing administering vaccines are important for prevention. The PPV23 PCV13 available Chinese market primarily produced by domestic manufacturers. potential risk increased IPD caused non-vaccine serotypes should be considered. Here, we review current status IPD, vaccines, their quality control We also address challenges future directions making progress controlling emphasizing need further evaluation burden monitoring effectiveness vaccination efforts.

Язык: Английский

Процитировано

1
The microbiological characteristics and diagnosis of Streptococcus pneumoniae infection in the conjugate vaccine era DOI Creative Commons
Chih-Ho Chen,

Chyi-Liang Chen,

Lin Su

и другие.

Human Vaccines & Immunotherapeutics, Год журнала: 2025, Номер 21(1)

Опубликована: Апрель 27, 2025

Two pneumococcal conjugate vaccines, PCV15 and PCV20, were licensed in June 2021. includes two additional serotypes (22F, 33F) beyond those PCV13, while PCV20 adds seven more (8, 10A, 11A, 12F, 15B, 22F, 33F), covering approximately 30% of invasive disease (IPD) cases adults. In 2023, the US CDC's Advisory Committee on Immunization Practices (ACIP) recommended either or for all children aged < 5 years 2‒18 with risk conditions. 2024, FDA approved PCV21 adults ≥ 18 years. October ACIP alone PPSV23 50 19-49 These advancements highlight evolving landscape vaccination. This review examines molecular epidemiology infections, diagnostic methods, anticipated public health impact these vaccines reducing burden.

Язык: Английский

Процитировано

0
The New Era of Pneumococcal Vaccination in Adults: What Is Next? DOI Creative Commons
Lale Özışık

Vaccines, Год журнала: 2025, Номер 13(5), С. 498 - 498

Опубликована: Май 7, 2025

Streptococcus pneumoniae remains the leading cause of community-acquired pneumonia in adults and bacterial meningitis children worldwide. In addition to pneumonia, invasive pneumococcal diseases (IPDs), such as bacteremia meningitis, pose a significant burden, particularly among older individuals with underlying comorbidities. These lead substantial morbidity mortality. Pneumococcal vaccination has been cornerstone disease prevention, reducing incidence antimicrobial resistance. Recent advances understanding S. epidemiology, genomic diversity, real-world impact conjugate vaccines have driven development licensure new-generation expanded serotype coverage. Introducing 15-valent (PCV15), 20-valent (PCV20), 21-valent (PCV21) reshaped immunization strategies, adults, replacing previous sequential vaccine recommendations many settings. parallel, emerging epidemiological data shifts distribution continue influence policy decisions guidelines light these advancements, adult continuously evolve enhance protection high-risk populations optimize long-term immunity. This review provides an updated overview evolution vaccines, latest strategies expanding landscape. Additionally, we discuss future directions potential novel approaches on public health outcomes.

Язык: Английский

Процитировано

0
Pneumococcal serotype distribution and coverage of existing and pipeline pneumococcal vaccines DOI Creative Commons
Laura King, Kristin L. Andrejko,

Miwako Kobayashi

и другие.

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Дек. 13, 2024

ABSTRACT Background Streptococcus pneumoniae (pneumococcus) causes invasive pneumococcal disease (IPD) and non-invasive acute respiratory infections (ARIs). Three conjugate vaccines (PCVs) are recommended in the United States with additional products clinical trials. We aimed to estimate 1) proportions of IPD cases ARIs caused by serotypes targeted existing pipeline PCVs 2) annual U.S. burdens potentially preventable PCVs. Methods estimated serotype distribution (AOM [children only], sinusitis, non-bacteremic pneumonia) attributable each PCV using Markov chain Monte Carlo approaches incorporating data from studies Active Bacterial Core Surveillance (ABCs) data. then numbers outpatient-managed ARIs, pneumonia hospitalizations, multiplying incidence rates PCV-targeted vaccine effectiveness estimates. Results In children, PCV15, PCV20, PCV24, PCV25, PCV31 account for 16% (95% confidence interval: 15–17%), 31% (30–32%), 34% (32–35%), 43% (42–44%), 68% (67–69%) otitis media cases, respectively. adults, PCV21, (38–47%), 52% (47–57%), 69% (64–73%), 65% (61–70%), 62% (57–67%), 87% (83–90%) cases. For IPD, 42–85% pediatric 42–94% adult were due serotypes. PCV-preventable encompassed 270 thousand–3.3 million 2–17 thousand 3–14 annually. Conclusions Across conditions, coverage lowest PCV15 highest PCV31, PCV21 also targeting sizeable disease. Serotype across syndromes may inform formulations policy.

Язык: Английский

Процитировано

1
A cell-free workflow for detecting and characterizing RiPP recognition element-precursor peptide interactions DOI Creative Commons
Derek A. Wong, Zachary M. Shaver, Maria D. Cabezas

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Март 26, 2024

Abstract Post-translational modifications (PTMs) are important for the stability and function of many therapeutic proteins peptides. Current methods studying engineering PTM installing often suffer from low-throughput experimental techniques. Here we describe a generalizable, in vitro workflow coupling cell-free protein synthesis (CFPS) with AlphaLISA rapid expression testing proteins. We apply our to two representative classes peptide therapeutics: ribosomally synthesized post-translationally modified peptides (RiPPs) conjugate vaccines. First, demonstrate how can be used characterize binding activity RiPP recognition elements, an first step biosynthesis, integrated into biodiscovery pipeline computationally predicted products. Then, adapt study engineer oligosaccharyltransferases (OSTs) involved vaccine production, enabling identification mutant OSTs sites within carrier that enable high efficiency production In total, expect will accelerate design-build-test cycles PTMs.

Язык: Английский

Процитировано

0